Basilea Pharmaceutica Presents Late-Breaker Data For Its Novel Antifungal Agent BAL8557, Confirming Its Broad Spectrum Of Activity Including Difficult Yeast And Mold Infections

BASEL, Switzerland, Dec. 20, 2005 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) presents positive phase II clinical trial data on its water-soluble azole BAL8557 in a late-breaker abstract at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington D.C. Six additional posters confirm its excellent potency against fluconazole-resistant yeasts and its promising activity against difficult-to-treat molds.